Dural Adhesive Agent for Surgical Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application (Cranial Surgery, Spinal Surgery), By Type (Polyethylene glycol, Others (Fibrin Glue)), By Form (Sealant Glue, Sealant Film) ,By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 213.31 Million
CAGR (2026-2031)	5.61%
Fastest Growing Segment	Cranial Surgery
Largest Market	North America
Market Size (2031)	USD 295.97 Million

Market Overview

The Global Dural Adhesive Agent for Surgical Market will grow from USD 213.31 Million in 2025 to USD 295.97 Million by 2031 at a 5.61% CAGR. Dural adhesive agents are specialized surgical sealants and glues applied during neurosurgical and spinal procedures to repair the dura mater and prevent cerebrospinal fluid leakage. The market is primarily driven by the rising global volume of cranial and spinal surgeries, necessitated by an aging population and the increasing prevalence of traumatic injuries that require operative intervention. Additionally, the clinical imperative to minimize post-operative complications and shorten patient recovery times significantly supports the adoption of these adjunct sealants over traditional suturing methods alone.

According to the American Spine Registry, in 2025, the registry recorded a 17.86% increase in submitted spine procedures compared to the previous year, indicating a robust upward trajectory in surgical demand. Despite this growth, one significant challenge impeding market expansion is the high cost associated with advanced biological and synthetic adhesive products, which restricts their broad adoption in cost-constrained healthcare systems and developing regions.

Key Market Drivers

The rising incidence of neurological and spinal disorders serves as the primary catalyst for the global dural adhesive agent market, as these conditions frequently necessitate complex surgical interventions where dural repair is critical. High rates of central nervous system malignancies and spinal injuries drive the volume of procedures requiring effective sealing to prevent cerebrospinal fluid leaks. According to the American Cancer Society, January 2025, in the 'Cancer Facts & Figures 2025', an estimated 24,820 malignant tumors of the brain or spinal cord were projected to be diagnosed in the United States. This substantial patient burden is further evidenced by global trauma statistics. According to Ageing Research Reviews, January 2025, in the study 'Global, regional, and national burden of spinal cord injury...', the global incidence of spinal cord injury reached 574,502 cases in the most recent analysis year, underscoring the consistent demand for surgical repair solutions to mitigate post-operative complications.

Advancements in biocompatible and synthetic dural sealant technologies are accelerating market adoption by addressing the critical clinical need for effective cerebrospinal fluid leak prevention. Surgeons are increasingly shifting towards advanced matrices and hydrogels that offer superior tissue adhesion and reduced complication rates compared to traditional suturing methods. The commercial traction of these innovative technologies is evident in the financial performance of market leaders specializing in regenerative solutions. According to Integra LifeSciences, November 2024, in the 'Third Quarter 2024 Financial Results', the company reported that its Tissue Technologies segment, which encompasses its dural repair portfolio, generated 110.1 million dollars in revenue. This revenue stream highlights the significant investment healthcare providers are making in high-quality adhesive agents to ensure optimal patient recovery and minimize expensive readmissions.

Download Free Sample Report

Key Market Challenges

The high acquisition cost associated with advanced biological and synthetic dural adhesives presents a substantial barrier to their widespread adoption in the global surgical market. While these products offer clinical benefits, their premium pricing often exceeds the budgetary limits of many healthcare institutions, particularly in developing regions and public health systems operating under strict financial caps. Surgeons and procurement departments frequently face pressure to prioritize cost-effective alternatives, such as traditional sutures, especially for routine procedures where the added expense of a sealant may not be deemed strictly necessary.

This economic strain is further evidenced by rising operational costs within the healthcare sector which limits the purchasing power for premium surgical adjuncts. According to the American Hospital Association, in 2024, total hospital expenses grew by 5.1%, a rate that significantly outpaced overall economic inflation. This escalating financial burden compels medical facilities to implement rigorous cost-containment strategies, often resulting in the reduced procurement of expensive, non-mandatory medical supplies. Consequently, manufacturers of dural adhesives face difficulty penetrating markets where price sensitivity outweighs the demand for advanced post-operative solutions.

Key Market Trends

The development of applicators specifically engineered for minimally invasive neurosurgery is transforming the utilization of dural adhesive agents. As surgeons increasingly adopt endoscopic endonasal approaches and keyhole craniotomies, the traditional syringe-based delivery of sealants has proven inadequate for reaching deep, narrow surgical corridors. Manufacturers are responding by introducing extended, flexible catheter-based applicators and spray tips that allow for precise, controlled deposition of the sealant in hard-to-access dural defects without obstructing the surgeon's view. This evolution addresses the critical workflow need for efficiency and ease of use in confined spaces, directly supporting the expansion of minimally invasive techniques. The commercial demand for such user-centric surgical adjuncts is reflected in the financial growth of key market players; according to Baxter International Inc., November 2024, in the 'Third Quarter 2024 Results', the Advanced Surgery segment reported sales of 272 million dollars, reflecting a 7% increase driven by strong demand for its hemostat and sealant portfolio.

Simultaneously, there is a distinct shift toward fully bioabsorbable and biodegradable formulations designed to optimize long-term post-operative outcomes. Unlike earlier generations of sealants that could leave permanent residue, the current market trend favors hydrogel matrices that degrade completely via hydrolysis within a predictable timeframe, typically 30 to 45 days. This characteristic is vital for preventing "mass effect," where residual sealant compresses neural tissue, and for ensuring that the material does not mimic tumor recurrence on follow-up MRI scans, a common issue with radio-opaque or permanent adhesives. This focus on "clean" healing and imaging clarity is becoming a standard requirement for complex spinal and cranial procedures. The scale of the sector demanding these high-performance, biocompatible solutions is substantial; according to Medtronic, May 2024, in the 'Full Year and Fourth Quarter Fiscal 2024 Financial Results', the Neuroscience Portfolio generated 9.4 billion dollars in revenue, underscoring the massive market for advanced technologies that support intricate nervous system repairs.

Segmental Insights

Cranial surgery currently represents the fastest-expanding segment within the global dural adhesive agent market, primarily driven by the rising prevalence of neurological disorders and traumatic brain injuries. These conditions frequently necessitate craniotomies, which increases the demand for effective dural closure products to prevent cerebrospinal fluid leakage. The segment growth is further supported by product clearances from regulatory bodies like the US Food and Drug Administration, validating the safety of these sealants for neurosurgical use. Consequently, surgeons are increasingly adopting these agents to ensure optimal postoperative outcomes and minimize complications associated with dural repair.

Regional Insights

North America maintains a leading position in the global dural adhesive agent for surgical market due to the high volume of neurosurgical and spinal procedures performed in the region. This dominance is supported by well-established healthcare infrastructure and comprehensive reimbursement policies that enable frequent product usage. Additionally, the U.S. Food and Drug Administration (FDA) plays a critical role by granting approvals that validate product safety and foster market trust. The strong presence of major manufacturers in the United States further ensures consistent product availability and drives adoption across hospitals and surgical centers.

Recent Developments

• In April 2025, Baxter International Inc. expanded its advanced surgery portfolio in Europe with the launch of a new version of its Hemopatch Sealing Hemostat featuring room temperature storage capabilities. This product evolution was designed to improve operational efficiency in hospitals by eliminating the need for refrigeration, thereby ensuring the hemostat is immediately accessible for surgical teams. Indicated for use as an adjunct to dural closure techniques to seal small defects, the product aims to support effective hemostasis and dural sealing. The President of Advanced Surgery at Baxter stated that this innovation was a direct response to surgeon feedback regarding the need for more convenient and rapidly deployable surgical solutions.
• In November 2024, Integra LifeSciences Holdings Corporation announced the publication of a significant economic evaluation in the Journal of Comparative Effectiveness Research. The company-sponsored study assessed the budget impact of using its polyethylene glycol hydrogel dural sealant versus fibrin glue in posterior fossa surgeries across five European countries. The research concluded that utilizing the hydrogel sealant could lead to substantial cost savings for hospitals by effectively reducing the incidence of cerebrospinal fluid leaks and associated postoperative complications. The Executive Vice President of Integra LifeSciences noted that these findings reinforced the clinical and economic value of their dural sealant portfolio in the global market.
• In June 2024, Product Creation Studio entered into a strategic partnership with PatchClamp Medtech Inc. to collaborate on the development of a specialized dural repair graft placement system. This cooperation aimed to combine the engineering and design expertise of Product Creation Studio with PatchClamp’s innovative medical device technology to address the challenges of closing dural defects during minimally invasive and open craniospinal surgeries. The collaboration focused on refining a system capable of delivering a precise, watertight seal to improve patient outcomes and reduce complications such as cerebrospinal fluid leakage, with the goal of accelerating the device's path to market.
• In March 2024, a multidisciplinary team of researchers spearheaded by faculty members from the Wyss Institute unveiled findings regarding a novel dural repair material known as the Dural Tough Adhesive. Detailed in the journal Science Translational Medicine, the study demonstrated that this new hydrogel-based adhesive offered superior performance compared to existing commercial sealants when tested on in vivo animal models and ex vivo human tissues. The breakthrough research highlighted the material’s enhanced biocompatibility, high adhesive strength, and ability to withstand significant intracranial pressures, positioning it as a potentially transformative solution for preventing cerebrospinal fluid leaks in neurosurgical procedures.

Key Market Players

• Medprin Biotech GmbH
• Integra LifeSciences Corporation
• Pramand LLC
• Stryker Corporation
• DuraStat, Inc.
• Medtronic plc
• Becton, Dickinson and Company
• Regenity Biosciences
• Baxter International, Inc.
• Johnson & Johnson

By Application	By Type	By Form	By Region
Cranial Surgery Spinal Surgery	Polyethylene glycol Others (Fibrin Glue)	Sealant Glue Sealant Film	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Dural Adhesive Agent for Surgical Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Dural Adhesive Agent for Surgical Market, By Application:

• Cranial Surgery
• Spinal Surgery

• Dural Adhesive Agent for Surgical Market, By Type:

• Polyethylene glycol
• Others (Fibrin Glue)

• Dural Adhesive Agent for Surgical Market, By Form:

• Sealant Glue
• Sealant Film

• Dural Adhesive Agent for Surgical Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE